Skip to main content

Table 2 Patients characteristics and outcomes

From: A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome

Case Dose of peptide (mg) Age Sex PS Site of desease Previous treatment* IFN γ response to each peptide Number of vaccination Period of vaccinations (days) Toxicity Response Prognosis (days) Treatments after vaccination
R T K R1 R2 Injection site reaction General PFS OS
Pre vaccinations
Within 3 courses of vaccinations
Within 6 courses of vaccinations
1 0.5 56 M 0 LN IRI, OX, FU ++ – – – – 85 2150 2 None CR 2150 2150 A None
– – + ++ –
+ ++ + ++ –
2 0.5 72 F 1 Lung, bone IRI, OX, FU – – – – – 16 120 1 None PD 60 191 D None
+ – – – +
+ + – – +
3 0.5 75 M 1 Liver, lung IRI, OX, FU – – ++ – – 27 364 1 None SD 158 406 D OX, FU, BEV
++ – – – +
++ – + – +
4 1 59 F 2 Dissemi. IRI, OX, FU – – – – – 8 49 1 None PD 36 80 D None
++ – – – –
++ – + – +
5 1 68 M 0 Lung IRI, OX, FU – – – – – 25 329 2 None PD 68 1009 D OX, FU, IRI, BEV, CETU
++ + ++ + ++
++ + ++ + ++
6 1 69 M 2 Lung, LN IRI, OX, FU – – + – – 13 84 2 None PD 62 110 D None
– ++ – – –
– ++ – – –
8 3 85 F 1 Dissemi. FU – – – – – 11 70 2 None PD 103 461 D IRI, FU
– – – + –
– – – + –
9 3 59 M 0 Lung IRI, OX, FU + – – – – 45 777 2 None SD 221 885 D None
++ ++ ++ ++ –
++ ++ ++ ++ –
10 3 49 F 0 Liver, lung IRI, FU ++ – – – – 39 777 2 Fever <38.0°C PD 69 834 D OX, FU, IRI, BEV
+++ – ++ ++ +
+++ – ++ ++ +
11 3 46 F 0 Lung none – – – – – 13 64 2 Erythena (G1) SD 117 1029 D OX, FU, IRI, BEV
– + ++ +++ ++
– + ++ +++ ++
12 3 71 M 0 Local OX, FU – – – – – 63 959 2 None SD 120 1059 D IRI, FU, OX, BEV
+ ++ ++ – +
+ ++ ++ + +
13 3 71 M 2 Liver, lung, bone IRI, OX, FU, RAD – – – – – 8 49 1 None PD 57 133 D None
– ++ ++ – –
– ++ ++ – –
14 3 (mix) 65 F 2 Dissemi. IRI, OX, FU – – – – – 8 49 1 None PD 50 342 D None
+ + ++ + ++
+ + ++ + ++
15 3 (mix) 71 M 2 Liver, lung IRI, OX, FU – – – – – 8 49 1 None PD 36 102 D None
+ – – +++ ++
+ – – +++ ++
16 3 (mix) 57 M 1 Local none – – ++ – – 38 749 2 None SD 771 1161 D None
+ – – +++ +++
+ ++ – +++ +++
17 3 (mix) 65 M 1 Dissemi. OX, FU – + – +++ – 16 126 2 None PD 69 145 D None
+ + + +++ +
+ + + +++ +
18 3 (mix) 55 F 0 Local IRI, FU – + + – – 8 49 2 None SD 56 56 A Curative resection
– – + – –
– – + – –
19 3 (mix) 58 F 2 Liver, Dissemi. OX, FU, BEV – ++ + – + 8 49 1 None PD 37 52 D None
++ + ++ – +
++ + ++ – +
  1. PS: Eastern Cooperative Oncology Group performance status, LN: lymph nodes, Dessemi: peritoneal dissemination, PFS: progression free survival, OS: over all survival.
  2. IRI: irinotican, OX: oxaliplatin, FU: fluoropyrimidine, RAD: radiation, BEV: bevacizumab, CETU: cetuximab, R: RNF43, T: TOMM34, K: KOC1, R1: VEGFR1, R2: VEGFR2, D: daed, A: alive.
  3. CR:complete response, PR: partial response, SD: stable desease, PD: progression desease, *: operation was performed for all patients for the resection of primary lesions.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us